Julie Delyon
YOU?
Author Swipe
View article: PDE4D drives rewiring of the MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors
PDE4D drives rewiring of the MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors Open
In summary, our research showed that PDE4D drives rewiring of the MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors and suggests that PDE4 inhibition is a novel therapeutic option for treatment of BRAF-mutated melanoma pat…
View article: BJD Reviewers January 2023–December 2023
BJD Reviewers January 2023–December 2023 Open
View article: TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro Open
Because BRAF-mutated melanomas are addicted to the Mitogen Activated Protein Kinase (MAPK) pathway they show a high response rate to BRAF and MEK inhibitors. However, the clinical responses to these inhibitors are often short-lived with th…
View article: Figure S3 from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i><sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
Figure S3 from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i><sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism Open
Figure S3. DNA alterations (mutations and copy number alterations) uncovered in all samples collected before and during treatment (Baseline, after cycle 2 and end of treatment). * indicates samples processed only in mRNA expression and cop…
View article: Figure S4 from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i><sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
Figure S4 from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i><sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism Open
Figure S4. Differential gene expression analysis in responders vs nonresponders conducted on baseline samples. Three hundred fifty-eight genes were screened. Genes with FDR P-value <0.05 are labeled and in blue.
View article: Supplementary Tables from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i><sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
Supplementary Tables from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i><sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism Open
Tables S1, S2, S3, S4
View article: Data from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i><sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
Data from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i><sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism Open
Purpose:In BRAFV600MUT metastatic melanoma, cyclin D–CDK4/6–INK4–Rb pathway alterations are involved in resistance to MAPK inhibitors, suggesting a clinical benefit of cyclin-dependent kinase 4 (CDK4) inhibitors. In this …
View article: Figure S2 from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i><sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
Figure S2 from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i><sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism Open
Figure S2. (A) Change in the tumor burden from baseline over time according to RECIST for all the included patients. The tumor burden was measured as the sum of the longest diameters of target lesions. Each line represents a patient. (B) K…
View article: Supplementary Materials and Methods from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i><sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
Supplementary Materials and Methods from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i><sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism Open
Supplementary Materials and Methods
View article: Figure S2 from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i><sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
Figure S2 from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i><sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism Open
Figure S2. (A) Change in the tumor burden from baseline over time according to RECIST for all the included patients. The tumor burden was measured as the sum of the longest diameters of target lesions. Each line represents a patient. (B) K…
View article: Figure S3 from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i><sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
Figure S3 from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i><sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism Open
Figure S3. DNA alterations (mutations and copy number alterations) uncovered in all samples collected before and during treatment (Baseline, after cycle 2 and end of treatment). * indicates samples processed only in mRNA expression and cop…
View article: Data from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i><sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
Data from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i><sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism Open
Purpose:In BRAFV600MUT metastatic melanoma, cyclin D–CDK4/6–INK4–Rb pathway alterations are involved in resistance to MAPK inhibitors, suggesting a clinical benefit of cyclin-dependent kinase 4 (CDK4) inhibitors. In this …
View article: Figure S1 from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i><sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
Figure S1 from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i><sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism Open
Figure S1. (A) RNA expression and copy number variations in A375 melanoma cell lines resistant to vemurafenib (A375R). RNA expression was normalized according to PPIA, B2M and ACTB gene expression (siRNA: small interfering RNA). (B) Inhibi…
View article: Figure S4 from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i><sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
Figure S4 from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i><sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism Open
Figure S4. Differential gene expression analysis in responders vs nonresponders conducted on baseline samples. Three hundred fifty-eight genes were screened. Genes with FDR P-value <0.05 are labeled and in blue.
View article: Figure S1 from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i><sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
Figure S1 from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i><sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism Open
Figure S1. (A) RNA expression and copy number variations in A375 melanoma cell lines resistant to vemurafenib (A375R). RNA expression was normalized according to PPIA, B2M and ACTB gene expression (siRNA: small interfering RNA). (B) Inhibi…
View article: Supplementary Materials and Methods from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i><sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
Supplementary Materials and Methods from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i><sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism Open
Supplementary Materials and Methods
View article: Supplementary Tables from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i><sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
Supplementary Tables from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i><sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism Open
Tables S1, S2, S3, S4
View article: Endemic Kaposi’s Sarcoma
Endemic Kaposi’s Sarcoma Open
Kaposi’s sarcoma (KS) is a common neoplasm in Eastern and central Africa reflecting the spread of human gammaherpesvirus-8 (HHV-8), now considered a necessary causal agent for the development of KS. The endemic KS subtype can follow an agg…
View article: A differential process mining analysis of COVID-19 management for cancer patients
A differential process mining analysis of COVID-19 management for cancer patients Open
During the acute phase of the COVID-19 pandemic, hospitals faced a challenge to manage patients, especially those with other comorbidities and medical needs, such as cancer patients. Here, we use Process Mining to analyze real-world therap…
View article: 18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors
18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors Open
Background: Immune checkpoint inhibitors (ICI) are currently the first-line treatment for patients with metastatic melanoma. We investigated the value of positron emission tomography (PET) response criteria to assess the therapeutic respon…
View article: Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma: A Retrospective Study
Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma: A Retrospective Study Open
Sonidegib, a hedgehog pathway inhibitor, is indicated for treatment of locally advanced basal cell carcinoma, based on the results of the BOLT study. However, to date, no real-world study of sonidegib has been reported. An observational, r…
View article: Yield of FDG PET/CT for Defining the Extent of Disease in Patients with Kaposi Sarcoma
Yield of FDG PET/CT for Defining the Extent of Disease in Patients with Kaposi Sarcoma Open
Background: Positron emission tomography/computed tomography with fluorodeoxyglucose (F-18) (FDG PET/CT) is increasingly used in Kaposi sarcoma (KS), but its value has not been assessed. Objectives: In this study, we aimed to evaluate the …
View article: Systemic Treatment Initiation in Classical and Endemic Kaposi’s Sarcoma: Risk Factors and Global Multi-State Modelling in a Monocentric Cohort Study
Systemic Treatment Initiation in Classical and Endemic Kaposi’s Sarcoma: Risk Factors and Global Multi-State Modelling in a Monocentric Cohort Study Open
Background: Although several studies described the clinical course of epidemic and post-transplant Kaposi’s Sarcoma (KS), the lack of large cohorts of classic/endemic KS, precluded such characterization. Methods: We used multi-state modell…
View article: Long-Term Outcome of Neoadjuvant Tyrosine Kinase Inhibitors Followed by Complete Surgery in Locally Advanced Dermatofibrosarcoma Protuberans
Long-Term Outcome of Neoadjuvant Tyrosine Kinase Inhibitors Followed by Complete Surgery in Locally Advanced Dermatofibrosarcoma Protuberans Open
In locally advanced dermatofibrosarcoma protuberans (DFSP), imatinib mesylate has been described as an efficient neoadjuvant therapy. This retrospective study included patients with locally advanced DFSP who received neoadjuvant TKI (imati…
View article: Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i> V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i> V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism Open
Purpose: In BRAFV600MUT metastatic melanoma, cyclin D–CDK4/6–INK4–Rb pathway alterations are involved in resistance to MAPK inhibitors, suggesting a clinical benefit of cyclin-dependent kinase 4 (CDK4) inhibitors. In this phase I–II study,…
View article: Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy Open
View article: Increased risk of brain metastases among patients with melanoma and PROM2 expression in metastatic lymph nodes
Increased risk of brain metastases among patients with melanoma and PROM2 expression in metastatic lymph nodes Open
International audience
View article: A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans
A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans Open
View article: Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases
Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases Open
Importance: Few data are available on patients with leptomeningeal disease (LM) from melanoma treated with new systemic therapies. Objective: To gain a better understanding of patients, disease characteristics, and therapeutic intervention…
View article: Increased Risk of Brain Metastases Among Patients with Melanoma and PROM2 Expression in Metastatic Lymph Nodes
Increased Risk of Brain Metastases Among Patients with Melanoma and PROM2 Expression in Metastatic Lymph Nodes Open
Background: Melanoma brain metastases are the main cause of specific death among patients with metastatic melanoma. The biology of melanoma brain metastases remains largely to be deciphered, as there have been only a few genomic studies on…